Evidence map›Paper›PMID 41724861›Full record

ArticleFunctional & integrative genomics2026

Bronchial epithelial-derived exosomal SLC6A14 promotes airway inflammation and mucus hypersecretion via the ZFP36L1/IL-8 axis.

Yurong Xiao, Yuanhang Jia, Lin Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yurong XiaoPulmonary and Critical Care Medicine, the Second Affiliated Hospital, University of South China, Hengyang, Hunan, China.
Yuanhang JiaPulmonary and Critical Care Medicine, the Second Affiliated Hospital, University of South China, Hengyang, Hunan, China.
Lin ChenPulmonary and Critical Care Medicine, the Second Affiliated Hospital, University of South China, Hengyang, Hunan, China. linzi200409@126.com.

Funding

Hunan Provincial Natural Science Foundation of China 2023JJ60352
6 · The paper itself

Abstract

SLC6A14 is an exosomal protein derived from bronchial epithelial cells. This study aims to investigate how exosomal SLC6A14 contributes to airway inflammation and mucus hypersecretion in chronic obstructive pulmonary disease (COPD).An in vitro COPD model was established by treating normal human bronchial epithelial cells (BEAS-2B) with 8% cigarette smoke extract (CSE) for 48 h. Interventions included SLC6A14 overexpression, ZFP36L1 overexpression, and exosome treatment. For the in vivo experiments, a COPD mouse model was induced by long-term cigarette smoke (CS) exposure for 6 months, and exosomes were administered during the final 2 weeks. Levels of inflammatory cytokines and mucin secretion were measured by RT-qPCR, ELISA, and Western blot. Lung tissue pathology, fibrosis, goblet cell hyperplasia, and mucus expression were analyzed using HE staining, Masson staining, immunohistochemistry, and multiplex immunofluorescence. An in vitro COPD model was established by treating normal human bronchial epithelial cells (BEAS-2B) with 8% cigarette smoke extract (CSE) for 48 h. Interventions included SLC6A14 overexpression, ZFP36L1 overexpression, and exosome treatment. For the in vivo experiments, a COPD mouse model was induced by long-term cigarette smoke (CS) exposure for 6 months, and exosomes were administered during the final 2 weeks. Levels of inflammatory cytokines and mucin secretion were measured by RT-qPCR, ELISA, and Western blot. Lung tissue pathology, fibrosis, goblet cell hyperplasia, and mucus expression were analyzed using HE staining, Masson staining, immunohistochemistry, and multiplex immunofluorescence. SLC6A14 expression was significantly upregulated in the lungs of CS-exposed mice and in CSE-treated BEAS-2B cells. Its overexpression triggered inflammatory responses and mucin expression in BEAS-2B cells irrespective of CSE treatment. Mechanistically, SLC6A14 could enhance IL-8 mRNA stability by suppressing the RNA-binding protein ZFP36L1. Comparatively, ZFP36L1 overexpression reduced CSE-induced inflammation and mucin expression in BEAS-2B cells by decreasing IL-8 mRNA. Exosomes released from CSE-treated BEAS-2B cells, which were enriched in SLC6A14, promoted inflammation and mucin secretion in recipient BEAS-2B cells. Importantly, exosomes isolated from the SLC6A14-silenced and CSE-treated BEAS-2B cells significantly alleviated airway inflammation, goblet cell hyperplasia, fibrosis, and mucus hypersecretion in CS-exposed mice. CSE stimulated bronchial epithelial cells to release exosomes enriched with SLC6A14, and these exosomes aggravated COPD-related airway inflammation and mucus hypersecretion by disrupting the ZFP36L1/IL-8 signaling axis.

Indexed as

Butyrate Response Factor 1ExosomesInterleukin-8MucusPulmonary Disease, Chronic ObstructiveAnimalsBronchiCell LineEpithelial CellsHumansInflammationMaleMiceMice, Inbred C57BLButyrate Response Factor 1Interleukin-8COPDExosomeIL-8 mRNASLC6A14ZFP36L1

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.